Friday, June 12, 2009 1:35:19 PM
Ardea Biosciences lead drug candidate shows promising interim results in midstage study
On Thursday June 11, 2009, 3:19 pm EDT
SAN DIEGO (AP) -- Ardea Biosciences Inc. said Thursday its lead drug candidate showed promising interim results in a midstage study aimed at treating gout and hyperuricemia.
Both conditions involve a higher-than-normal level of uric acid in the bloodstream, leading to symptoms such as swelling and pain in joints. The study on RDEA594 involves 20 patients.
So far, 86 percent of patients have responded to the drug. On average, patients taking the drug candidate had a 40 percent reduction in uric acid levels.
Full dosing in the study is expected to be complete in late June, with full study results planned for a presentation at an upcoming scientific conference, the company said.
"These very encouraging interim data from our Phase 2a study have confirmed the activity and safety of RDEA594 in gout patients and our formulation and dose selections for the upcoming Phase 2b program," said Ardea President and Chief Executive Barry D. Quart, in a statement.
Shares of Ardea Biosciences rose 50 cents, or 3.3 percent, to reach $15.74 in afternoon trading. The stock has traded between $6.29 and $16.75 over the past 52 weeks.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM